NEWEarnings

Barclays Lowers Stock Rating for Terns Pharmaceuticals Amid Merck Deal

Published on 3/30/2026

#TernsPharmaceuticals#Barclays#Merck#StockRating#Investors
Barclays Lowers Stock Rating for Terns Pharmaceuticals Amid Merck Deal

AI Summary

Barclays has downgraded the stock rating for Terns Pharmaceuticals, citing the recent deal with Merck. This change could influence investor sentiment and trading volumes for Terns Pharmaceuticals as the market reacts to the adjustment in outlook. The specifics of the rating change were not disclosed in the report. Analyst ratings can significantly impact stock prices and market positioning.

Source: Read original article (opens in new tab)

Related News

Eli Lilly and Insilico Partner on AI Drug Development Deal Valued at $2.75B
Earnings

Eli Lilly and Insilico Partner on AI Drug Development Deal Valued at $2.75B

Mar 30

Booz Allen Hamilton Stock Analysis: Performance Metrics and Risks
Earnings

Booz Allen Hamilton Stock Analysis: Performance Metrics and Risks

Mar 29

Alamo Group Inc. (ALG) Stock Analysis: Key Metrics and Considerations
Earnings

Alamo Group Inc. (ALG) Stock Analysis: Key Metrics and Considerations

Mar 29

Allison Transmission Holdings, Inc. Reports Q3 Financial Results
Earnings

Allison Transmission Holdings, Inc. Reports Q3 Financial Results

Mar 29